"NEW SECTION.  Sec. 1   The legislature finds that voter approval of Initiative Measure No. 502 established a system for licensing and regulating cannabis production, processing, and sale. The legislature further finds that this new industry is projected to create new jobs and generate revenues to the state estimated as high as $1,943,936,000 over five fiscal years. The legislature also finds that qualifying patients have additional protections under chapter 69.51A RCW. The legislature further finds there is potential interest to expand into other areas, such as industrial hemp, food processing, farmers' markets, and banking. As such, given a potentially evolving demand and market in new areas, it is the intent of the legislature to create a state cannabis industry coordinating committee to promote and further develop the industry while remaining in compliance with federal guidelines. It is the intention of the legislature that the committee will coordinate and monitor new developments and their impact on Washington state, and to make recommendations to the legislature on establishment of a state comprehensive plan.
     The legislature also finds that, while the state liquor control board is working to implement the regulatory structure enacted by Initiative Measure No. 502, additional issues need to be addressed. The use of medical marijuana outside of this regulatory structure, the process for medical authorizations, the establishment of medical dispensaries, and other related issues should be addressed by a statewide committee that would submit its policy recommendations for consideration by the 2015 legislature.

NEW SECTION.  Sec. 2   (1) A state cannabis industry coordinating committee is established, with members as provided in this subsection.
     (a) The president of the senate shall appoint one member from each of the two largest caucuses of the senate.
     (b) The speaker of the house of representatives shall appoint one member from each of the two largest caucuses of the house of representatives.
     (c) Each of the following agencies shall appoint a representative to serve on the committee:
     (i) The liquor control board;
     (ii) The department of health;
     (iii) The department of revenue;
     (iv) The department of agriculture; and
     (v) The department of financial institutions.
     (d) The governor shall appoint three members representing medical marijuana stakeholders as follows:
     (i) Two qualifying patients or advocates; and
     (ii) A marijuana licensee.
     (e) One representative each from the association of Washington cities and the Washington state association of counties.
     (f) The governor may appoint up to five industry stakeholders representing established and emerging markets for the use of cannabis including, but not limited to, the various commercial uses of industrial hemp, food processing, farmers' markets, tourism, banking, or other uses that may be relevant.
     (2) The committee must appoint its cochairs, at least one of whom must be from among its legislative membership. The committee shall make rules for orderly procedure and appoint the subcommittee required in subsection (3) of this section.
     (3) The committee shall appoint a medical marijuana subcommittee, which must be chaired by a legislative member of the committee, for the purpose of reviewing and making recommendations on the issues in (a) through (g) of this subsection. The subcommittee may consult with other entities as the subcommittee deems appropriate.
     (a) Whether there is a need for retail outlets that are licensed to only sell medical marijuana to qualifying patients or designated providers;
     (b) Whether the use of valid documentation should be permitted as an alternative to registering with the medical marijuana registry;
     (c) Whether a marijuana producer or marijuana processor endorsement should be established to permit a producer or processor to sell directly to qualifying patients and designated providers and whether these licensees are producing marijuana concentrates, useable marijuana, and marijuana-infused products that are meeting the needs of medical marijuana patients;
     (d) Whether posttraumatic stress disorder should be added to terminal or debilitating medical conditions that qualify a person for the medical use of marijuana;
     (e) Whether a different method of taxation should be established for those products designated by the liquor control board as being beneficial for qualifying patients and designated providers. This includes whether these products should be taxed at a different rate than products intended for nonmedical use or whether they should be provided with tax exemptions;
     (f) Whether and how qualifying patients or designated providers should be authorized to form a cooperative to share responsibility for acquiring and supplying the resources needed to produce and process marijuana solely for the medical use of members of the cooperative or for medical research; and
     (g) Any other matters the committee determines are pertinent to promoting access to safe and affordable marijuana for medical use by qualifying patients.
     (4) The committee has the following powers and duties:
     (a) Developing a state comprehensive plan that identifies and coordinates the various business and economic opportunities within the cannabis industry, including potential opportunities;
     (b) Recommending a state financial system that best implements the state's marijuana marketplace while maximizing public safety, accurate tax accounting, and compliance with the United States attorney general's guidance regarding marijuana enforcement and guidance regarding marijuana-related financial crimes on implementation of Initiative Measure No. 502;
     (c) Making recommendations for a statewide cannabis industry coordinator;
     (d) Making recommendations on options for the distribution of tax revenue from the sale of marijuana; and
     (e) Making recommendations specific to the medical use of marijuana as described in subsection (3) of this section.
     (5) The committee shall provide specific preliminary recommendations to the appropriate committees of the legislature by December 15, 2014, and a final report by January 10, 2016.
     (6) Staff support for the committee must be provided by senate committee services, the house of representatives office of program research, and the represented state agencies.
     (7) Legislative members of the committee must serve without additional compensation, but must be reimbursed for travel expenses in accordance with RCW 44.04.120. Nonlegislative members, except those representing an employer or organization, are entitled to be reimbursed for travel expenses in accordance with RCW 43.03.050 and 43.03.060.
     (8) The expenses of the committee must be paid jointly by the senate and the house of representatives. Committee expenditures are subject to approval by the senate facilities and operations committee and the house of representatives executive rules committee, or their successor committees.
     (9) This section expires January 31, 2016."